Under the terms of the cooperative R&D agreement, National Institute of Neurological Diseases and Stroke (NINDS) will deliver NeoPharm’s proprietary drug, Cintredekin Besudotox (IL13-PE38QQR) (IL-13), in conjunction with a surrogate marker via NINDS’s patented methodology of convection enhanced delivery, which was previously licensed to NeoPharm.
The company will provide both the drug and technical resources to study its effects in various brain cancers in humans.
Laurence Birch, president and CEO of NeoPharm, said: “This cooperative R&D agreement serves as another step in pursuing the validation of IL-13’s impact on possibly increasing and enhancing the life span of patients diagnosed with terminal brain cancers.”